I Want To...
Find a Doctor
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
Nancy A. Ator, Ph.D.
Director, Division of Behavioral Biology
Professor of Psychiatry and Behavioral Sciences
Research Interests: Behavioral pharmacology and drug abuse; Preclinical characterization of anxiolytics, hypnotics; In vivo characterization of selective GABAergic compounds to determine behavioral relevance of novel in-vitro activity with respect to drug abuse; Study of interoceptive stimulus functions of psychoactive drugs ...read more
- Director, Division of Behavioral Biology
- Professor of Psychiatry and Behavioral Sciences
Johns Hopkins University School of Medicine, Baltimore, Maryland, 1978
Research & Publications
Ator NA, Weerts EM, Kaminski, BJ, Kautz MA, Griffiths RR. Zaleplon and triazolam physical dependence assessed across increasing doses under a once-daily dosing regimen in baboons. Drug and Alcohol Dependence:61:69-84. (2000)
Ator NA, Kautz MA. Differentiating benzodiazepine and barbituate-like discriminative stimulus effects of lorazepam, diazepam, pentobarbital, imidazenil, and zaleplon in two versus three lever procedures. Behavioural Pharmacology:11:1-14. (2000)
Ator NA. Zaleplon and triazolam: Drug discrimination, plasma levels, and self-administration in baboons. Drug and Alcohol Dependence: 61:69-84. (2000)
Ator NA. Relation between discriminative and reinforcing effects of midazolam, pentobarbital, chlordiazepoxide, zolpidem, and imidazenil in baboons. Psychopharmacology: 163:477-487. (2002)
Ator NA, Griffiths RR. Principles of drug abuse liability assessment in laboratory animals. Drug and Alcohol Dependence: 70: S55-S72. (2003)
Ator NA. Contributions of GABAa receptor subtype selectivity to abuse liability and dependence potential of pharmacological treatments for anxiety and sleep disorders. CNS Spectrums:10: 31-39. (2005)
Ator, N. A., Atack, J. R., Hargreaves, R. J., Burns, H. D., and Dawson, G. R. (2010) Reducing abuse liability of GABAA/benzodiazepine ligands via selective partial-agonist efficacy at α1 and α2/3 subtypes. Journal of Pharmacology and Experimental Therapeutics, 332: 4-16. (Published online September 29, 2009; doi:10.1124/jpet.109.158303)